BioDelivery Sciences International Inc. (NASDAQ:BDSI) shot up 3.6% on Friday . The company traded as high as $2.91 and last traded at $2.90, with a volume of 496,807 shares. The stock had previously closed at $2.80.

A number of research firms have recently weighed in on BDSI. Cantor Fitzgerald reaffirmed a “hold” rating on shares of BioDelivery Sciences International in a research note on Saturday, July 9th. Piper Jaffray Cos. reissued an “overweight” rating and issued a $4.00 price objective (down from $6.00) on shares of BioDelivery Sciences International in a research note on Thursday, May 12th. Zacks Investment Research downgraded BioDelivery Sciences International from a “buy” rating to a “hold” rating in a research note on Wednesday, July 27th. FBR & Co raised their price objective on BioDelivery Sciences International from $9.00 to $12.00 and gave the company an “outperform” rating in a research note on Wednesday, May 4th. Finally, Janney Montgomery Scott reissued a “hold” rating and issued a $4.00 price objective on shares of BioDelivery Sciences International in a research note on Tuesday, July 12th. One analyst has rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $8.25.

The company has a 50-day moving average of $2.53 and a 200 day moving average of $2.94. The firm’s market cap is $154.48 million.

BioDelivery Sciences International (NASDAQ:BDSI) last posted its earnings results on Tuesday, August 9th. The specialty pharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.31). The business earned $5 million during the quarter, compared to analyst estimates of $3.35 million. During the same period in the previous year, the firm posted ($0.37) earnings per share. The firm’s revenue was up 194.1% on a year-over-year basis. On average, analysts anticipate that BioDelivery Sciences International Inc. will post ($1.14) earnings per share for the current year.

In other news, Director William B. Stone sold 16,000 shares of the company’s stock in a transaction dated Thursday, August 11th. The stock was sold at an average price of $2.57, for a total transaction of $41,120.00. Following the completion of the transaction, the director now directly owns 122,675 shares of the company’s stock, valued at $315,274.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.